We are living through a volatile political environment these days and a troubling phrase that has re-entered the Hoosier ...

We are living through a volatile political environment these days and a troubling phrase that has re-entered the Hoosier ...

We are living through a volatile political environment these days and a troubling phrase that has re-entered the Hoosier lexicon is this: "Domestic terrorism." ...

The G700’s off-road capability is built on the GAIA Architecture, which integrates the Super Hybrid iDM-Off road system to deliver 665kW (904hp) and 0-100 km/h in 4.6 seconds. Its high-pressure ...

Lexicon has pivoted back to a research-driven biotech model, abandoning internal drug marketing to focus on clinical development and out-licensing. Pilavapadin's upcoming Phase II readout is critical, ...

When Apple introduced “spatial audio” to Apple Music and the AirPods family, it quickly became a bigger buzzword in audio discussions. In just a few years, it has become ubiquitous. This popularity ...

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon Pharmaceuticals Inc ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...